OMEPRAZOLE AND SODIUM BICARBONATE

Post-LOE

omeprazole and sodium bicarbonate

Aurobindo Pharma

ANDAORALCAPSULE

Approved

Jul 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

OMEPRAZOLE AND SODIUM BICARBONATE (omeprazole and sodium bicarbonate) by Aurobindo Pharma is proton pump inhibitors [moa]. Approved for sodium bicarbonate for oral suspension is indicated in adults for: reduction of risk of upper gastrointestinal (gi) bleeding in critically ill patients (1). First approved in 2016.

Drug data last refreshed 20h ago

Mechanism of Action

Proton Pump Inhibitors

Pharmacologic Class:

Proton Pump Inhibitor

Indications (1)

Sodium Bicarbonate for oral suspension is indicated in adults for: Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients (1)

Company

Worked on OMEPRAZOLE AND SODIUM BICARBONATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.